Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
NCT04216472 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6
Last updated 2025-09-30
Summary
This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline refractory). Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nab-paclitaxel and alpelisib before surgery may help shrink the tumor before surgery.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Anatomic Stage IIB Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage II Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage IIB Breast Cancer AJCC v8
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Refractory Breast Carcinoma
- Triple-Negative Breast Carcinoma
Interventions
- DRUG
-
Alpelisib
Given PO
- DRUG
-
Given IV
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Senthilkumar Damodaran · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-05
- Primary Completion
- 2025-09-22
- Completion
- 2025-09-22
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02445391 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
NCT00087217 ·Status: COMPLETED ·Phase: PHASE1
-
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
NCT00612677 ·Status: TERMINATED ·Phase: PHASE2
-
Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00470249 ·Status: TERMINATED ·Phase: PHASE2
-
Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00016367 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
NCT02379416 ·Status: COMPLETED ·Phase: PHASE1
-
Paclitaxel and BMS-214662 in Treating Patients With Advanced Solid Tumors
NCT00006018 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor
NCT00004159 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
NCT05554380 ·Status: SUSPENDED ·Phase: PHASE2
-
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
NCT00482014 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors
NCT00307255 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00006116 ·Status: UNKNOWN ·Phase: PHASE2
-
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
NCT03304210 ·Status: COMPLETED ·Phase: PHASE1
-
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00112710 ·Status: UNKNOWN ·Phase: PHASE3
-
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00071136 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Abraxane and Alimta in Advanced Solid Tumors
NCT00470548 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
NCT01920061 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
NCT00159458 ·Status: TERMINATED ·Phase: PHASE2
-
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
NCT00004173 ·Status: UNKNOWN ·Phase: PHASE1
-
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
NCT02199418 ·Status: COMPLETED ·Phase: PHASE2
-
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
NCT01928160 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00022646 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
NCT00794417 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
NCT01918306 ·Status: TERMINATED ·Phase: PHASE1/PHASE2